Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
2.
Laboratory Medicine Online ; : 98-101, 2016.
Artigo em Inglês | WPRIM | ID: wpr-16398

RESUMO

Recent advances in chemotherapy have led to increased survival rates for patients with hematologic malignancies. However, standard chemotherapies, including alkylating agents for non-Hodgkin lymphoma, could induce therapy-related myeloid neoplasms (t-MNs), a group of disorders categorized by the World Health Organization in 2008. Here, we report a case of coexistence of bone marrow (BM)-involved refractory marginal zone B-cell lymphoma (MZL) and therapy-related myelodysplastic syndrome (t-MDS). Simultaneous presence of refractory lymphoma and t-MN in the BM is rare, and this is the first report in Korea. The patient received allogeneic hematopoietic stem cell transplantation (HSCT) to cure both the MZL and t-MDS. Since the HSCT, he has been stable for 21 months without any evidence of recurrence.


Assuntos
Humanos , Alquilantes , Medula Óssea , Tratamento Farmacológico , Neoplasias Hematológicas , Transplante de Células-Tronco Hematopoéticas , Coreia (Geográfico) , Linfoma , Linfoma de Zona Marginal Tipo Células B , Linfoma não Hodgkin , Síndromes Mielodisplásicas , Recidiva , Taxa de Sobrevida , Organização Mundial da Saúde
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA